Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- Check4 days agoChange DetectedA new 'Revision: v3.3.3' label appears on the page, while the 'HHS Vulnerability Disclosure' and the 'Revision: v3.3.2' entries are removed from the footer.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe latest record now shows Revision: v3.3.2 in the history, with v3.3.1 removed from the list. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedRevision: v3.3.1 replaces v3.2.0; no substantive changes to the study record content or data are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the notice about government funding delays and potential information currency from the page header. The page now presents the standard study details without that disclaimer.SummaryDifference0.5%

- Check54 days agoChange DetectedNo significant content changes detected between the old and new versions; the updates appear to be minor UI/layout adjustments to the page header and navigation while study content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange Detected- Added a government funding notice about potential delays and current operating status, plus a link to cc.nih.gov and opm.gov for updates. - Bumped version from v3.1.0 to v3.2.0.SummaryDifference11%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.